- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02617654
Liraglutide Effect on Beta-cell Function in C-peptide Positive Type 1 Diabetes
A Randomized, Double-blinded Placebo-controlled, Paralleled Designed, Investigator Sponsored Study of the Effect of the GLP-1 Receptor Agonist Liraglutide on Beta-cell Function in C-peptide Positive Type 1 Diabetic Patients
Recent studies show that many Type 1 diabetes patients have remaining endogenous insulin production, albeit at low levels. Finding means to increase this production would be of tremendous interest, since residual C-peptide concentrations >0.1 nmol/l previously have been shown to markedly lower HbA1c, decrease blood glucose fluctuations and diminish the risk of ketoacidosis. It also substantially reduces the risks of severe hypoglycemic events and late complications. Liraglutide may through its incretin effect directly potentiate beta-cell function, but also holds the potential to be mitogenic for these cells.
The hypothesis of the present trial is that treatment with liraglutide will not only have a direct effect on beta-cell function, which is more or less immediately observed, but also progressively improve C-peptide concentrations over time.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Uppsala, Sweden, SE-75185
- Uppsala University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Written informed consent for participation of the study, given before undergoing any study-specific procedures.
- 18-30 years of age (age interval inclusive of both the ends). Both males and females are eligible for the study
- Clinical diagnose of T1D
- Five or more years duration of disease
- HbA1C between 45 and 75 mmol/mol
- Fasting plasma C-peptide concentration >1.5 pmol/l.
Exclusion Criteria:
- Inability to provide informed consent
- Mental incapacity
- Unwillingness or language barrier precluding adequate understanding or cooperation
- Ongoing or planned pregnancy within the next 12 months
- Inadequate or no use of contraceptives
- Ongoing breast feeding
- Known sight-threatening retinopathy
- Creatinine clearance <60 ml/min
- Life-threatening cardiovascular disease
- History of drug/alcohol abuse
- Known or suspected allergy to trial product or related product
- Recurrent assisted hypoglycemias
- Taking oral anti-diabetic therapies or any other concomitant medication which may interfere with glucose regulation other than insulin
- Uncontrolled hypertension (180/105 mmHg or above)
- History of acute or chronic pancreatitis
- Personal or family history of multiple endocrine neoplasia type 2 (MEN2) or familial medullary thyroid carcinoma (FMTC)
- Personal history of non-familial medullary thyroid carcinoma.
- Any condition that the investigator or sponsor feel would interfere with trial participation or evaluation of results
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Liraglutide treatment
Liraglutide treatment in the dose of 1.8 mg daily for 52 weeks
|
Treatment with liraglutide for 52 weeks
|
Placebo Comparator: Placebo treatment
Treatment with placebo once daily for 52 weeks
|
Placebo for liraglutide.
Treatment once daily for 52 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The effect of 52 weeks of treatment with liraglutide 1.8 mg/day, compared to placebo, on stimulated C-peptide concentrations in patients with long-standing type 1 diabetes and residual insulin production
Time Frame: 52 weeks
|
The Area Under the Curve (AUC) change in plasma C-peptide concentration in response to a standardized mixed meal tolerance test (MMTT) during one year of liraglutide treatment (1.8 mg/day)
|
52 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in C-peptide between 6 and 52 weeks of study
Time Frame: 52 weeks
|
∆- change in C-peptide AUC between the MMTT after one year and that after 6 weeks of treatment
|
52 weeks
|
Change in C-peptide between after and prior to treatment with liraglutide 1.8 mg
Time Frame: 52 weeks
|
∆-change in C-peptide AUC between the MMTT three months after cessation of treatment and that after the run-in period
|
52 weeks
|
Change in HbA1c between before and at end of liraglutide (1.8 mg) treatment
Time Frame: 52 weeks
|
∆- change in HbA1c between after one year and after the run-in period.
|
52 weeks
|
Change in HbA1c between 6 and 52 weeks of study
Time Frame: 52 weeks
|
∆- change in HbA1c between after one year and after 6 weeks of treatment
|
52 weeks
|
Change in HbA1c between after and prior to treatment with liraglutide 1.8 mg
Time Frame: 52 weeks
|
∆- change in HbA1c between three months after the cessation of treatment and after the run-in period.
|
52 weeks
|
Change in insulin doses between before and at end of liraglutide (1.8 mg) treatment
Time Frame: 52 weeks
|
∆- change in exogenous insulin doses between after one year and after the run-in period.
|
52 weeks
|
Change in insulin doses between 6 and 52 weeks of study
Time Frame: 52 weeks
|
∆- change in exogenous insulin doses between after one year and after 6 weeks of treatment
|
52 weeks
|
Change in insulin doses between after and prior to treatment with liraglutide 1.8 mg
Time Frame: 52 weeks
|
∆- change in exogenous insulin doses between three months after the cessation of treatment and after the run-in period.
|
52 weeks
|
Change in glucose variability between before and at end of liraglutide (1.8 mg) treatment
Time Frame: 52 weeks
|
∆- change in glucose variability between after one year and after the run-in period.
|
52 weeks
|
Change in glucose variability between 6 and 52 weeks of study
Time Frame: 52 weeks
|
∆- change in glucose variability between after one year and after 6 weeks of treatment
|
52 weeks
|
Change in glucose variability between after and prior to treatment with liraglutide 1.8 mg
Time Frame: 52 weeks
|
∆- change in glucose variability between three months after the cessation of treatment and after the run-in period.
|
52 weeks
|
Change in hypoglycemia frequency between before and at end of liraglutide (1.8 mg) treatment
Time Frame: 52 weeks
|
∆- change in hypoglycemia frequency (measured plasma glucose levels < 3 mmol/l or assisted hypoglycemia during a one week period) between one year and after the run-in period.
|
52 weeks
|
Change in hypoglycemia frequency between 6 and 52 weeks of study
Time Frame: 52 weeks
|
∆- change in hypoglycemia frequency (measured plasma glucose levels < 3 mmol/l or assisted hypoglycemia during a one week period) after one year and after 6 weeks of treatment
|
52 weeks
|
Change in hypoglycemia frequency between after and prior to treatment with liraglutide 1.8 mg
Time Frame: 52 weeks
|
∆- change in hypoglycemia frequency (measured plasma glucose levels < 3 mmol/l or assisted hypoglycemia during a one week period) between three months after the cessation of treatment and after the run-in period.
|
52 weeks
|
Change in Quality of Life (QoL) between before and at end of liraglutide (1.8 mg)
Time Frame: 52 weeks
|
∆- change in assessment of QoL between after one year and after the run-in period.
|
52 weeks
|
Change in QoL between 6 and 52 weeks of study
Time Frame: 52 weeks
|
∆- change in assessment of QoL between after one year and after 6 weeks of treatment
|
52 weeks
|
Change in QoL between after and prior to treatment with liraglutide
Time Frame: 52 weeks
|
∆- change in assessment of QoL between three months after the cessation of treatment and after the run-in period.
|
52 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- U1111-1166-6923
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 1 Diabetes
-
Poznan University of Medical SciencesUnknownDiabetes Mellitus Type 1 | Remission of Type 1 Diabetes | Chronic Complications of DiabetesPoland
-
Eledon PharmaceuticalsWithdrawnBrittle Type 1 Diabetes MellitusUnited States
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Hoffmann-La RocheCompletedType 2 Diabetes, Type 1 DiabetesAustria, United Kingdom
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
NYU Langone HealthNational Heart, Lung, and Blood Institute (NHLBI)Recruiting
-
Rabin Medical CenterDreaMed DiabetesTerminated
Clinical Trials on Liraglutide
-
Woman'sNovo Nordisk A/SCompletedPolycystic Ovary Syndrome | Pre Diabetes | Obesity AndroidUnited States
-
Novo Nordisk A/SCompleted
-
The Affiliated Hospital of Qingdao UniversityCompletedTherapeutic EquivalencyChina
-
Merck Sharp & Dohme LLCCompleted
-
Sunshine Lake Pharma Co., Ltd.Completed
-
Henrik GudbergsenCompletedObesity | OsteoarthritisDenmark
-
Parker Research InstituteCompletedOsteoarthritis, KneeDenmark
-
Henrik GudbergsenCompletedObesity | OsteoarthritisDenmark
-
Henrik GudbergsenNovo Nordisk A/S; Cambridge Weight Plan LimitedCompleted
-
Henrik GudbergsenCompletedUltrasound of the Knee in Obese Patients With Knee Osteoarthritis; Weight Maintenance (US-LOSEIT-II)Obesity | OsteoarthritisDenmark